ISDA

Entry Detail

PDB ID:

6SKC

Keywords:

HYDROLASE

Title:

Crystal Structure of Human Kallikrein 6 (I218Y) in complex with GSK3448330A

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Baculovirus expression vector pFastBac1-HM

PDB Version:

Deposition Date:

2019-08-15

Release Date:

2019-09-25

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.18 Å

R-Value Free:

0.24

R-Value Work:

0.18

R-Value Observed:

0.19

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Kallikrein-6
Mutations:I218Y
Chain IDs:A, B
Chain Length:223
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q92876 Pfam ID:PF00089 EC:3.4.21.104

Ligand Molecules

BEN

GOL

LH8

Primary Citation

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

Walker, A.L, Denis, A, Bingham, R.P, Boulliot, A, Edgar, E.V, Ferrie, A, Holmes, D.S, Laroze, A, Liddle, J, Fouchet, M.H, Moquette, A, Nassau, P, Pearce, A.C, Polyakova, O, Smith, K.J, Thomas, P, Thorpe, J.H, Trottet, L, Wang, Y, Hovnanian, A.Show

Bioorg.Med.Chem.Lett. 29 126675 126675 (2019)

PMID: 31521475 DOI: 10.1016/j.bmcl.2019.126675

Abstact

The connection between Netherton syndrome and overactivation of epidermal/dermal proteases, particularly Kallikrein 5 (KLK5) has been well established and it is expected that a KLK5 inhibitor would improve the dermal barrier and also reduce the pain and itch that afflict Netherton syndrome patients. One of the challenges of covalent protease inhibitors has been achieving selectivity over closely related targets. In this paper we describe the use of structural insight to design and develop a selective and highly potent reversibly covalent KLK5 inhibitor from an initial weakly binding fragment.

Legend

Protein

Chemical

Disease

Primary Citation of related structures